Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × tagraxofusp × Clear all
NCT04342962 2025-01-30

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Terminated
25 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡